Loading…

Interleukin-35 is upregulated in response to influenza virus infection and secondary bacterial pneumonia

•We developed a murine model of postinfluenza pneumococcal pneumonia.•We collected Serum sample from 30 healthy individuals and 33 patients.•We found elevated pulmonary IL-35 induced by influenza infection following secondary pneumococcal infection. Postinfluenza pneumococcal pneumonia is an importa...

Full description

Saved in:
Bibliographic Details
Published in:Cytokine (Philadelphia, Pa.) Pa.), 2016-05, Vol.81, p.23-27
Main Authors: Chen, Yi, Wang, Chuan-jiang, Lin, Shi-hui, Zhang, Mu, Li, Sheng-yuan, Xu, Fang
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•We developed a murine model of postinfluenza pneumococcal pneumonia.•We collected Serum sample from 30 healthy individuals and 33 patients.•We found elevated pulmonary IL-35 induced by influenza infection following secondary pneumococcal infection. Postinfluenza pneumococcal pneumonia is an important cause of global morbidity and mortality. What causes this increased susceptibility is not well elucidated. IL-35 is a newly described cytokine in infectious tolerance. A murine model was established to study postinfluenza pneumococcal pneumonia and evaluate the role of IL-35 in host defense against postinfluenza pneumococcal pneumonia. Pulmonary IL-35 was rapidly up-regulated during murine influenza infection, which was partially mediated by type I IFN-α/β receptor signaling pathway. Secondary pneumococcal infection led to a synergistic IL-35 response in influenza-infected mice. Clinical analysis showed that IL-35 levels were significantly elevated in the patients with influenza infection compared with healthy individuals and influenza infection could induce IL-35 production from human peripheral blood mononuclear cells. These data suggest that IL-35 contributes to the increased susceptibility to secondary pneumococcal pneumonia at least in part by inhibiting the early immune response.
ISSN:1043-4666
1096-0023
DOI:10.1016/j.cyto.2016.01.016